US · TKNO · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Alpha Teknova, Inc. (TKNO) intrinsic value and stock valuation
$7.63as of 2026-11-21 · Mkt cap 346.35M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Alpha Teknova, Inc. DCF and intrinsic value
InvestorsCraft values TKNO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TKNO’s statements →
Alpha Teknova, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40.5M | $37.7M | $36.7M | $41.4M | $36.9M |
| Operating income | -$-16.98M | -$-26.15M | -$-35.56M | -$-49.66M | -$-12.01M |
| Net income | -$-17.26M | -$-26.75M | -$-36.78M | -$-47.47M | -$-9.8M |
| EPSd | -$-322.74K | -$-572.19K | -$-1.16M | -$-1.69M | -$-349.88K |
| Operating cash flow | -$-8.65M | -$-12.39M | -$-18.81M | -$-27.4M | -$-9.07M |
| Capital expenditure | -$-1.15M | -$-1.12M | -$-7.93M | -$-28.15M | -$-19.88M |
| Free cash flow | -$-9.79M | -$-13.52M | -$-26.75M | -$-55.55M | -$-28.95M |
| Total assets | $103.6M | $118.8M | $128.6M | $152.3M | $166.5M |
| Total debt | $15.2M | $30.2M | $30.5M | $42.3M | $11.9M |
| Net debt | $9.23M | $26.5M | $1.97M | $70K | -$-75.65M |
| Total equity | $68.8M | $82.4M | $90M | $99.9M | $143.2M |
| Cash and short-term investments | $5.91M | $30.4M | $28.5M | $42.2M | $87.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $40.5M | $37.7M | $36.7M | $41.4M | $36.9M |
| Cost of revenue | $27.1M | $30.5M | $26.4M | $23.9M | $19.3M |
| Gross profit | $13.4M | $7.23M | $10.3M | $17.5M | $17.6M |
| Research and development expenses | $2.2M | $2.76M | $5.57M | $7.74M | $4.31M |
| Selling, general and administrative expenses | $27.1M | $29.5M | $34.8M | $37.5M | $24.2M |
| Other expenses | $1.15M | $1.15M | $5.51M | $22M | $1.15M |
| Operating expenses | $30.4M | $33.4M | $45.9M | $67.1M | $29.6M |
| Cost and expenses | $57.5M | $63.9M | $72.3M | $91.1M | $48.9M |
| Interest income | $0.00 | $0.00 | $0.00 | $210K | $0.00 |
| Interest expense | $710K | $690K | $830K | $0.00 | $590K |
| Depreciation and amortization | $6.34M | $6.58M | $5.66M | $3.17M | $2.88M |
| Ebitda | -$-10.15M | -$-19.57M | -$-25.54M | -$-25.69M | -$-9.16M |
| Operating income | -$-16.98M | -$-26.15M | -$-35.56M | -$-49.66M | -$-12.01M |
| Total other income/expenses, net | -$-230K | -$-690K | -$-1.51M | $270K | -$-630K |
| Income before tax | -$-17.2M | -$-26.83M | -$-37.08M | -$-49.39M | -$-12.64M |
| Income tax expense | $60K | -$-90K | -$-300K | -$-1.92M | -$-2.83M |
| Net income | -$-17.26M | -$-26.75M | -$-36.78M | -$-47.47M | -$-9.8M |
| Weighted average shares outstanding | $53.5M | $46.8M | $31.8M | $28.1M | $28M |
| Weighted average diluted shares outstanding | $53.5M | $46.8M | $31.8M | $28.1M | $28M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.91M | $30.4M | $28.5M | $42.2M | $87.5M |
| Net receivables | $4.62M | $4.31M | $3.95M | $4.28M | $5.85M |
| Inventory | $7.05M | $6.8M | $11.6M | $12.3M | $5.39M |
| Total current assets | $34.5M | $42.8M | $45.7M | $61.1M | $101.2M |
| Property, plant and equipment, net | $55.8M | $61.5M | $66.8M | $71.3M | $29.8M |
| Goodwill and intangible assets | $11.9M | $13.1M | $14.2M | $17.6M | $35.3M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $69.1M | $76M | $82.9M | $91.1M | $65.3M |
| Total assets | $103.6M | $118.8M | $128.6M | $152.3M | $166.5M |
| Accounts payable | $1.38M | $820K | $1.49M | $2.45M | $2.25M |
| Short-term debt | $1.88M | $5.84M | $1.8M | $2.22M | $0.00 |
| Deferred revenue | $0.00 | $30K | $20K | $200K | $200K |
| Total current liabilities | $7.54M | $11.2M | $8.88M | $10.9M | $7.74M |
| Long-term debt | $13.3M | $24.3M | $28.7M | $40.1M | $11.9M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $27.3M | $25.2M | $29.7M | $41.5M | $15.6M |
| Capital lease obligations | $0.00 | $16.7M | $17.2M | $20.3M | $0.00 |
| Total liabilities | $34.8M | $36.4M | $38.6M | $52.4M | $23.3M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-135.79M | -$-118.53M | -$-91.79M | -$-55.01M | -$-7.54M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $68.8M | $82.4M | $90M | $99.9M | $143.2M |
| Total investments | $0.00 | $26.7M | $0.00 | $0.00 | $0.00 |
| Total debt | $15.2M | $30.2M | $30.5M | $42.3M | $11.9M |
| Net debt | $9.23M | $26.5M | $1.97M | $70K | -$-75.65M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-17.26M | -$-26.75M | -$-36.78M | -$-47.47M | -$-9.8M |
| Depreciation and amortization | $6.34M | $6.58M | $5.66M | $3.17M | $2.88M |
| Stock-based compensation | $3.43M | $3.67M | $4.14M | $3.71M | $1.55M |
| Change in working capital | -$-2.68M | -$-870K | $2.25M | -$-7.33M | -$-1.77M |
| Accounts receivable | -$-370K | -$-490K | $310K | $380K | -$-50K |
| Inventory | -$-2.37M | $240K | $330K | -$-7.55M | -$-2.25M |
| Accounts payable | $470K | -$-590K | -$-770K | $570K | $270K |
| Net cash provided by operating activities | -$-8.65M | -$-12.39M | -$-18.81M | -$-27.4M | -$-9.07M |
| Investments in property, plant and equipment | -$-1.15M | -$-1.12M | -$-7.93M | -$-28.15M | -$-19.88M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $10.7M | -$-27.27M | -$-7.74M | -$-28.15M | -$-17.52M |
| Common stock issued | $210K | $15.1M | $22.5M | $440K | $102.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $150K | $14.9M | $12.8M | $10.3M | $110.8M |
| Net change in cash | $2.2M | -$-24.78M | -$-13.75M | -$-45.28M | $84.2M |
| Cash at end of period | $5.91M | $3.71M | $28.5M | $42.2M | $87.5M |
| Operating cash flow | -$-8.65M | -$-12.39M | -$-18.81M | -$-27.4M | -$-9.07M |
| Capital expenditure | -$-1.15M | -$-1.12M | -$-7.93M | -$-28.15M | -$-19.88M |
| Free cash flow | -$-9.79M | -$-13.52M | -$-26.75M | -$-55.55M | -$-28.95M |
Line items
Line items
Line items
About Alpha Teknova, Inc.
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
- CEO
- Stephen Gunstream
- Employees
- 158
- Beta
- 0.63
Explore
Frequently asked questions
What is the intrinsic value of Alpha Teknova, Inc. (TKNO)?
Alpha Teknova, Inc. (TKNO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TKNO undervalued?
TKNO trades at a price of $7.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.